HomeCompareGCPEF vs JNJ

GCPEF vs JNJ: Dividend Comparison 2026

GCPEF yields 1428.57% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GCPEF wins by $450506417.87M in total portfolio value
10 years
GCPEF
GCPEF
● Live price
1428.57%
Share price
$0.14
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$450506417.90M
Annual income
$395,979,768,203,621.75
Full GCPEF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — GCPEF vs JNJ

📍 GCPEF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGCPEFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GCPEF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GCPEF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GCPEF
Annual income on $10K today (after 15% tax)
$121,428.57/yr
After 10yr DRIP, annual income (after tax)
$336,582,802,973,078.50/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, GCPEF beats the other by $336,582,802,969,092.50/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GCPEF + JNJ for your $10,000?

GCPEF: 50%JNJ: 50%
100% JNJ50/50100% GCPEF
Portfolio after 10yr
$225253208.96M
Annual income
$197,989,884,104,155.56/yr
Blended yield
87.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

GCPEF
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
0.7
Piotroski
1/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GCPEF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGCPEFJNJ
Forward yield1428.57%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$450506417.90M$30.3K
Annual income after 10y$395,979,768,203,621.75$4,689.40
Total dividends collected$446517047.78M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: GCPEF vs JNJ ($10,000, DRIP)

YearGCPEF PortfolioGCPEF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$153,557$142,857.14$10,592$272.30+$143.0KGCPEF
2$2,214,468$2,050,162.12$11,289$357.73+$2.20MGCPEF
3$30,000,943$27,631,462.06$12,123$472.89+$29.99MGCPEF
4$381,953,954$349,852,945.12$13,141$629.86+$381.94MGCPEF
5$4,571,417,058$4,162,726,327.26$14,408$846.81+$4571.40MGCPEF
6$51,453,661,727$46,562,245,474.49$16,021$1,151.60+$51453.65MGCPEF
7$544,851,809,170$489,796,391,122.49$18,122$1,588.22+$544851.79MGCPEF
8$5,430,224,629,042$4,847,233,193,230.08$20,930$2,228.20+$5430224.61MGCPEF
9$50,959,485,695,016$45,149,145,341,941.08$24,792$3,191.91+$50959485.67MGCPEF
10$450,506,417,897,289$395,979,768,203,621.75$30,274$4,689.40+$450506417.87MGCPEF

GCPEF vs JNJ: Complete Analysis 2026

GCPEFStock

GCL Technology Holdings Limited manufactures and sells polysilicon and wafers products in the People's Republic of China and internationally. It operates through three segments: Solar Material Business, Solar Farm Business, and New Energy Business. The Solar Material Business segment primarily manufactures and sells polysilicon and wafer products to companies operating in the solar industry. The Solar Farm Business segment operates and manages 18 MW solar farms located in the United States and 150 MW solar farms situated in South Africa; and 5 solar farms in the People's Republic of China. The New Energy Business segment develops, constructs, operates, and manages solar farms. The company was formerly known as GCL-Poly Energy Holdings Limited and changed its name to GCL Technology Holdings Limited in April 2022. GCL Technology Holdings Limited was incorporated in 2006 and is based in Kowloon, Hong Kong.

Full GCPEF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this GCPEF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GCPEF vs SCHDGCPEF vs JEPIGCPEF vs OGCPEF vs KOGCPEF vs MAINGCPEF vs ABBVGCPEF vs MRKGCPEF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.